Efficacy of a novel chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against four common tick species infesting dogs in Europe

Table 2 Arithmetic mean live Dermacentor reticulatus counts for dogs dosed once orally with sarolaner + moxidectin + pyrantel and efficacy relative to placebo (Study 2)

Count day	Placebo		1.2 mg/kg sarolaner + 24 µg moxidectin + 5 mg/kg pyrantel			Test statistic (vs placebo)
Count day	Mean	Range	Mean^a	Range	% Efficacy	Test statistic (vs placebo)
2	29.8	20–37	0.3	0–1	99.2	t₍₁₄₎ = 23.43 P < 0.0001
7	36.5	30–45	0	0	100	t₍₁₄₎ = 79.48 P < 0.0001
14	30.3	15–37	0.1	0–1	99.6	t₍₁₄₎ = 24.22 P < 0.0001
21	33.6	20–47	0.1	0–1	99.6	t₍₁₄₎ = 25.55 P < 0.0001
28	35.8	22–45	1.0	0–5	97.2	t₍₁₄₎ = 11.42 P < 0.0001
35	24.7	18–36	3.9	0–15	84.3	t₍₁₄₎ = 12.22 P < 0.0001

Note: Dogs infested with ticks from colony originated from the UK and subsequently enriched with ticks from Slovakia, Germany and the Netherlands, the last time 2 years before study conduct
^aMean live tick count significantly lower than placebo (11.42 ≤t₍₁₄₎ ≤ 79.48, P < 0.0001) at all time points

ISSN: 1756-3305